Coherus Biosciences Stock Current Valuation
| CHRS Stock | USD 1.10 0.28 34.15% |
Valuation analysis of Coherus BioSciences helps investors to measure Coherus BioSciences' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to gain to -3.39 in 2024. Enterprise Value Multiple is likely to gain to -3.39 in 2024. Fundamental drivers impacting Coherus BioSciences' valuation include:
Price Book 73.1897 | Enterprise Value 298.9 M | Enterprise Value Ebitda 8.0167 | Price Sales 0.4164 | Forward PE 26.5252 |
Overvalued
Today
Please note that Coherus BioSciences' price fluctuation is abnormally volatile at this time. Calculation of the real value of Coherus BioSciences is based on 3 months time horizon. Increasing Coherus BioSciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Coherus stock is determined by what a typical buyer is willing to pay for full or partial control of Coherus BioSciences. Since Coherus BioSciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Coherus Stock. However, Coherus BioSciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.1 | Real 0.95 | Target 12.63 | Hype 1.1 | Naive 1.18 |
The intrinsic value of Coherus BioSciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Coherus BioSciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Coherus BioSciences helps investors to forecast how Coherus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Coherus BioSciences more accurately as focusing exclusively on Coherus BioSciences' fundamentals will not take into account other important factors: Coherus BioSciences Company Current Valuation Analysis
Coherus BioSciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Coherus BioSciences Current Valuation | 298.92 M |
Most of Coherus BioSciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Coherus BioSciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Coherus Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Coherus BioSciences is extremely important. It helps to project a fair market value of Coherus Stock properly, considering its historical fundamentals such as Current Valuation. Since Coherus BioSciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Coherus BioSciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Coherus BioSciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Coherus BioSciences has a Current Valuation of 298.92 M. This is 97.92% lower than that of the Biotechnology sector and 93.57% lower than that of the Health Care industry. The current valuation for all United States stocks is 98.2% higher than that of the company.
Coherus Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Coherus BioSciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Coherus BioSciences could also be used in its relative valuation, which is a method of valuing Coherus BioSciences by comparing valuation metrics of similar companies.Coherus BioSciences is currently under evaluation in current valuation category among its peers.
Coherus BioSciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Coherus BioSciences from analyzing Coherus BioSciences' financial statements. These drivers represent accounts that assess Coherus BioSciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Coherus BioSciences' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.3B | 1.2B | 1.2B | 614.8M | 313.6M | 518.3M | |
| Enterprise Value | 1.3B | 1.1B | 1.2B | 1.0B | 691.5M | 539.3M |
Coherus Fundamentals
| Return On Equity | -16.57 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 298.92 M | ||||
| Shares Outstanding | 115.21 M | ||||
| Shares Owned By Insiders | 1.39 % | ||||
| Shares Owned By Institutions | 70.09 % | ||||
| Number Of Shares Shorted | 31.51 M | ||||
| Price To Earning | 4.22 X | ||||
| Price To Book | 73.19 X | ||||
| Price To Sales | 0.42 X | ||||
| Revenue | 257.24 M | ||||
| Gross Profit | (58.4 M) | ||||
| EBITDA | (193.94 M) | ||||
| Net Income | (237.89 M) | ||||
| Cash And Equivalents | 275.48 M | ||||
| Cash Per Share | 3.54 X | ||||
| Total Debt | 480.84 M | ||||
| Current Ratio | 3.17 X | ||||
| Book Value Per Share | (0.76) X | ||||
| Cash Flow From Operations | (174.88 M) | ||||
| Short Ratio | 11.95 X | ||||
| Earnings Per Share | (0.09) X | ||||
| Target Price | 6.5 | ||||
| Number Of Employees | 235 | ||||
| Beta | 0.69 | ||||
| Market Capitalization | 126.73 M | ||||
| Total Asset | 629.6 M | ||||
| Retained Earnings | (1.58 B) | ||||
| Working Capital | 143.86 M | ||||
| Current Asset | 197.39 M | ||||
| Current Liabilities | 106.02 M | ||||
| Net Asset | 629.6 M |
About Coherus BioSciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Coherus BioSciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coherus BioSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coherus BioSciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.